Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06402955 · ClinicalTrials.gov registry record · Phase 2
Imaging Depression in Parkinson's Disease
A Phase 2 study of Major Depressive Disorder and Parkinson's Disease, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06402955 is a Phase 2 study of Major Depressive Disorder and Parkinson's Disease that is actively recruiting participants, run by Yale University. The registered enrollment target is 120 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06402955, a Phase 2 study of Major Depressive Disorder and Parkinson's Disease, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.
Conditions Studied
Interventions
- RADIATION 11C-UCB-J
- DRUG ketamine hydrochloride
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-09-01 |
| Est. Completion | 2029-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06402955
The ClinicalTrials.gov registry entry for NCT06402955 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (68% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which 11C-UCB-J is the first listed.
NCT06402955 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT06402955 about?
NCT06402955 is a clinical study titled "Imaging Depression in Parkinson's Disease". The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.
What is the current status of trial NCT06402955?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-09-01. Estimated completion is 2029-12-01.
What conditions does trial NCT06402955 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Parkinson's Disease.
What interventions are being tested in trial NCT06402955?
The interventions under investigation include: 11C-UCB-J (RADIATION), ketamine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06402955?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06402955 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.